Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.9645
+0.0644 (7.15%)
At close: Aug 28, 2026, 4:00 PM EDT
0.9626
-0.0019 (-0.20%)
After-hours: Aug 28, 2026, 7:44 PM EDT
Invivyd Revenue
Invivyd had revenue of $14.29M in the quarter ending June 30, 2026, with 21.20% growth. This brings the company's revenue in the last twelve months to $58.37M, up 26.30% year-over-year. In the year 2025, Invivyd had annual revenue of $53.43M with 110.47% growth.
Revenue (ttm)
$58.37M
Revenue Growth
+26.30%
P/S Ratio
4.87
Revenue / Employee
$478,402
Employees
122
Market Cap
284.29M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.43M | 28.04M | 110.47% |
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Niagen Bioscience | 129.08M |
| Compugen | 74.00M |
| Alector | 13.86M |
| Adagene | 9.29M |
| Camp4 Therapeutics | 4.22M |
| Sol-Gel Technologies | 1.80M |
IVVD News
- 16 days ago - Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 16 days ago - Invivyd Earnings release: Q2 2026 - Filings
- 16 days ago - Invivyd Quarterly report: Q2 2026 - Filings
- 25 days ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Invivyd announces notice of termination for Pemgarda Emergency Use Authorization - TheFly
- 7 weeks ago - Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA - GlobeNewsWire
- 2 months ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer - GlobeNewsWire